Reatividade cruzada entre betalactâmicos: uma abordagem prática
Cross-reactivity among beta-lactams: a practical approach
Ullissis Pádua Menezes; Marcelo Vivolo Aun; Mara Morelo Rocha Felix; Adriana Teixeira Rodrigues; Ana Carolina D'Onofrio-Silva; Denise Neiva Santos de Aquino; Diogo Costa-Lacerda; Fernanda Casares Marcelino; Gladys Queiroz; Inês Cristina Camelo-Nunes; Luiz Alexandre Ribeiro da Rocha; Maria Inês Perelló; Tânia Maria Gonçalves de Souza Gomes; Maria Fernanda Malaman
Resumo
Os betalactâmicos são a classe de drogas que mais causam reações de hipersensibilidade envolvendo um mecanismo imunológico específico, e são os principais desencadeantes entre os antimicrobianos. São representados pelas penicilinas, cefalosporinas, carbapenêmicos, monobactâmicos e inibidores da betalactamase. A estrutura química básica destes fármacos consiste na presença dos seguintes componentes: anel betalactâmico, anel adjacente e cadeias laterais, sendo todos potenciais epítopos. Os anticorpos da classe IgE e linfócitos T estão frequentemente envolvidos no reconhecimento desses epítopos. A reatividade cruzada depende da estabilidade dos produtos intermediários (determinantes antigênicos) derivados da degradação dos anéis betalactâmicos, anéis adicionais e da semelhança estrutural das cadeias laterais entre as drogas. Classicamente acreditava-se num grande potencial de reatividade cruzada dentro de cada classe e até entre as classes, mas estudos da última década mostraram que indivíduos alérgicos à penicilina (com testes cutâneos positivos) reagiam às cefalosporinas em aproximadamente 3% dos casos, aos carbapenêmicos em cerca de 1%, e praticamente não reagiam aos monobactâmicos. Essa reatividade ou tolerância parece estar vinculada ao grau de similaridade entre as cadeias laterais desses antibióticos. Nesta revisão, ressaltamos a importância da investigação sistematizada na confirmação ou exclusão de alergia aos betalactâmicos, descrevemos a prevalência da reatividade cruzada entre estes fármacos e sugerimos um algoritmo de abordagem desses pacientes baseados em sua estrutura química e nos dados publicados na literatura.
Palavras-chave
Abstract
Beta-lactams are the drugs most commonly involved in hypersensitivity reactions mediated by a specific immune mechanism and are the main triggers among antibiotics. They include penicillins, cephalosporins, carbapenems, monobactams and beta-lactam inhibitors. The basic chemical structure of these drugs consist on the presence of the following components: betalactam ring, an adjacent ring and side chains, all of which are potential epitopes. IgE antibodies and T lymphocytes are often involved in recognizing those epitopes. Cross-reactivity depends on the stability of intermediate products (antigenic determinants) derived from the degradation of the beta-lactam ring, on the adjacent rings, and on the structural similarity of the side chains between drugs. Classically, it was believed that there was a great potential for cross-reactivity within each class and even between classes, but studies from the last decade showed that individuals allergic to penicillin (with positive skin tests) reacted to cephalosporins in approximately 3% of cases, to carbapenems in about 1%, and rarely reacted to monobactams. This reactivity or tolerance seems to be linked to the degree of similarity between the side chains of these antibiotics. In this review, we emphasize the importance of systematic investigation to confirm or exclude allergy to beta-lactams, we describe the prevalence of crossreactivity between these drugs and we suggest an algorithm for approaching these patients based on their chemical structure and on data published in the literature.
Keywords
Referências
1. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin Allergy: A Review. JAMA. 2019;321(2):188‑99.
2. Castells M, Khan DA, Phillips EJ. Penicillin Allergy. N England J Med. 2019;381:2338-51.
3. Sacco KA, Bates A, Brigham TJ, Imam JS, Burton MC. Clinical outcomes following in patient penicillin allergy testing: a systematic review and meta-analysis. Allergy. 2017;72(9):1288-96.
4. Huang KG, Cluzet V, Hamilton K, Faduga O. The impact of reported beta-lactam allergy in hospitalized patients with hematologic malignancies requiring antibiotics. Clin Infect Dis. 2018;67(1):27‑33.
5. Felix MMR, Aun MV, Menezes UP, Queiroz GRES, Rodrigues AT, D'Onofrio-Silva AC, et al. Allergy to penicillin and betalactam antibiotics. Einstein (São Paulo). 2021;19:1-13.
6. Macy E. Penicillin and Beta-lactam allergy epidemiology and diagnosis. Curr Allergy Asthma Rep. 201414:14:476.
7. Pichler WJ. Imune Pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457-71.
8. Khan Da, Banerji A, Bernstein JA, Bilgicer B, Blumenthal K, Castells M, et al. Cephalosporin Allergy: Current understanding and future challenges. J Allergy Clin Immunol Pract. 2019;7:2105-14.
9. Torres MJ, Blanca M. The complex clinical Picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am. 2010:94(4):805.
10. Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. Ann Allergy Asthma Immunol. 2014;112(5):404-12.
11. Zagursky RJ, Pichichero ME. Cross-reactivity in Beta-lactam allergy. J Allergy Clin Immunol Pract. 2018;6(1):72-81.
12. Blanca-Lopez N, Jimenez-Rodriguez TW, Somoza ML, Gomez E, Al-Ahmad M, Perez-Sala D, et al. Allergic reactions to penicillins and cephalosporins: diagnosis assessment of cross-reactivity and management. Exp Rev Clin Immunol. 2019;15(7):707-21.
13. Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019;74:14-27.
14. Doña I, Romano A, Torres MJ. Algorithm for betalactam allergy diagnosis. Allergy. 2019;74:1817-9.
15. Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams: an EAACI position paper. Allergy. 2020;75(6):1300-15.
16. Chiriac AM, Banerji A, Gruchalla RS, Thong BYH, Wickner P, Mertes PM, et al. Controversies in Drug Allergy: Drug Allergy Pathways. J Allergy Clin Immunol Pract. 2019;7(1):46-60.
17. Wurpts G, Aberer W, Dickel H, Brehler R, Jakob T, Kreft B et al. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics. Allergol Select. 2020;4:11-43.
18. Picard M, Robitaille G, Karam F, Daigle JM, Bédard F, Biron É, et al. Cross-reactivity to cephaslosporins and carbapenems in penicillinallergic patients: two systematic reviews and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(8):2722-38.
19. Romano A, Gaeta F, Poves MFA, Valluzzi RL. Cross-Reactivity among Beta-lactams. Curr Allergy Asthma Rep. 2016;16:1-12.
20. Chaudhry SB, Veve MP, WagnerJL. Cephalosporins: a focus on side chains and B-lactam cross-reactivity. Pharmacy. 2019;7(3):103:1‑16.
21. Rubin R. Overdiagnosis of penicillin allergy leads to costly, inappropriate treatment. JAMA. 2018;320(18):1846-8.
22. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicilillina “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol. 2014;133(3):790-6.
23. Caruso C, Valluzzi RL, Colantuono S, Gaeta F, Romano A. B-Lactam Allergy and Cross-Reactivity: A Clinician’s Guide to Selecting na Alternative Antibiotic. J Asthma Allergy. 2021;14:31-46.
24. Blanca-Lopez N, Perez-Alzate D, Ruano F, Garcimartin M, de la Torre V, Mayorga C, et al. Selective immediate responders to amoxicillin and clavulanic acid tolerate penicillin derivative administration after confirming the diagnosis. Allergy. 2015;70(8):1013-9.
25. Torres MJ, Romano A, Mayorga C, Moya MC, Guzman AE, Reche M, et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: the role of skin testing. Allergy. 2001;56:850-6.
26. Trcka J, Seitz CS, Brocker EB, Gross GE, Trautmann A. Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin. J Antimicrob Chemother. 2007;60(1):107-11.
27. Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol Pract. 2018;6(5):1662-72.
28. Caimmi S, Galéra C, Bousquet-Rouanet L, Arnoux B, DemolyP, Bousquet PJ. Safety of cefuroxime as an alternative in patients with a proven hypersensitivity to penicillins: a DAHD cohort survey. Int Arch Allergy Immunol. 2010;153(1):53-60.
29. Romano A, Valluzzi RL, Caruso C, Zaffiro A, Quaratino D, Gaeta F. Tolerability of Cefazolin and Ceftibuten in patients with IgEMediated Aminopenicillin allergy. J Allergy Clin Immunol Pract. 2020;9:1989‑93.
30. Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2016;138:179-86.
31. Atanaskovic-Markovic M, Gaeta F, Gavrovic-Jankulovic M, Velickovic TC, Valluzzi RL, Romano A. Tolerability of imipenem in children with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2009;124(1):167-9.
32. Gaeta F, Valluzzi RL, Alonzi C, Maggioletti M, Caruso C, Romano A. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to pencillins. J Allergy Clin Immunol. 2015;135(4):972-6.
33. Romano A, Gaeta F, Valluzzi RL, Alonzi C, Maggioletti M, Zaffiro A, et al. Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins. Allergy. 2013;68(12):1618‑21.
34. Antunez C, Blanca-Lopez N, Torres MJ, Mayorga C, Perez-Inestrosa E, Montañez MI, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephaslosporins. J Allergy Clin Immunol. 2006;117(2):404-10.
35. Li J, Green SL, Krupowicz BA, Capon MJ, Lindberg A, Hoyle P, et al. Cross-reactivity to penicillins in cephalosporin anaphylaxis. Br J Anaesth. 2019;123(6):e532-e534.
36. Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clin Infect Dis. 2014 Oct 15;59(8):1113-22.
37. Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol. 2010;126(5):994-9.
38. Sadleir Ph, Clarke RC, Platt PR. Cefalotin as antimicrobial prophylaxis in patients with known intraoperative anaphylaxis to cefazolin. Br J Anaesth. 2016;117(4):464-9.
39. Van Gasse AL, Ebo DG, Faber MA, Elst J, Hagendorens MM, Bridts CH, et al. Cross-reactivity in IgE-mediated allergy to cefuroxime: Focus on the R1 side chain. J Allergy Clin Immunol Pract. 2020;8(3):1094-96.
40. Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Zaffiro A, Caruso C, et al. IgE-mediated hypersensitivity to cephalosporins: Crossreactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol. 2015;136(3):685-91.
41. Touati N, Cardoso B, Delpuech M, Bazire R, El Kara N, Ouali D, et al. Cephalosporin Hypersensitivity: Descriptive Analysis, Cross-Reactivity, and Risk Factors. J Allergy Clin Immunol Pract. 2021;9(5):1994-2000.
Submetido em:
03/08/2021
Aceito em:
24/09/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email